HEPATITIS C– Highly competitive market due to large number of marketed drugs

NEW DELHI - Sept. 14, 2017 - PRLog -- The Hepatitis C arena currently has around 23 marketed drugs due to the increasing number of patients globally as per the latest report of DelveInsight. Hepatitis C is a potentially contagious, inflammatory liver disease caused by Hepatitis C virus (a blood borne virus). Hepatitis C infection can be of two types- Acute Hepatitis C infection, a short-term illness, which when remains untreated transforms into a long-term infection called as Chronic Hepatitis C. Hepatitis C infection can lead to serious and permanent liver damage, which sometimes results in acute liver failure and death.

According to "HEPATITIS C– Competitive Landscape, Market, and Pipeline Analysis, 2017", Due to the increasing number of Hepatitis C patients worldwide companies are now focused to develop more advanced and effective therapies for the treatment of the given indication. Currently, hepatitis market is loaded with a large number of marketed drugs but most of them are out of the reach of a maximum percentage of patients due to high price tags. Gilead Sciences is leading the market with 2 top selling drugs Sovaldi and Harvoni. Both the drugs are dominating the market with high sales record Sovaldi (USD 4001 million) and Harvoni (USD 9081 million) in 2016. Merck and Gilead are the market leaders with a maximum number of marketed drugs.

Hepatitis C pipeline is highly active with promising drug candidates. Currently, there are around 20 products active in the pipeline with 10% of the products in the phase I and phase II each and 7% in phase III. Roche has recently filed for the patent for its drug candidate Danoprevir. Abbvie successfully managed to get the patent approved by USFDA making it an active player in the Hepatitis C market. Most of the companies developing the drugs are working on Polymerase Inhibitors and Protease Inhibitors. According to the latest report of WHO approximately 0.39 million people die each year from hepatitis C. More and more companies are involving in this domain to fulfill all the unmet needs globally.

The latest report has covered detailed information about comparative analysis of therapeutic drugs at various stages and their therapeutic assessment by product type and molecule type. Detailed Historical and Forecasted Sales of Marketed Drugs is provided to understand the drug specific market share and the possible change in the present market scenario. Detailed pipeline portfolio including Filed, Phase III, Phase II, and Phase I products is provided to understand existing key players and upcoming market competition. Information about the various technologies involved in the development of pipeline therapeutics is covered in the report. Patent and Financing details related to the products are also provided to understand the legal and R&D strength of the company and the product associated with it.

Reasons to Buy:

·   The report will help in developing business strategies by understanding trends shaping and driving the Hepatitis C market.

·  To understand the future market competition in the Hepatitis C drug market and Insight reviews of the key market drivers and barriers.

·   Organize sales and marketing efforts by identifying the best opportunities for Hepatitis C in the US, Europe (Germany, Spain, Italy, France and the United Kingdom) and Japan.

·  Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.

·   Detailed information about the pipeline, marketed and inactive products to understand the exact scenario of the drug market globally.

Companies Covered:

·         Gilead Sciences

·         Roche

·         Merck

·         Janssen

·         Medivir

·         Achillion

·         Tibotec

·         Ascletis Pharmaceuticals

        And many others………………..

For more details please visit: http://bit.ly/2wr0jrK